Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.00 (0.00%)
Bid:
1.80
Ask:
2.00
Spread: 0.20 (11.111%)
Market Cap: £8.30m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Director/PDMR Shareholding - Replacement

22 Jun 2021 13:25

RNS Number : 7366C
Renalytix AI PLC
22 June 2021
 

The following amendment(s) has been made to the ' Director/PDMR Dealing' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.

 

The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

The Company was also informed of the sale 'yesterday'.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Renalytix AI plc 

 

("Renalytix" or the "Company")

 

Director/PDMR Dealing

 

The Company was informed that yesterday, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 1135 pence per share.

 

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.0025 each

Identification code

GB00BYWL4Y04

 

 

b)

 

Nature of the transaction

 

 

Sale of shares

c)

Currency

GBP

d)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

£11.352941

17,000

 

 

 

 

 

e)

 

Aggregated information

- Aggregated volume

17,000

- Price

£192,999.99

f)

 

Date of the transaction

 

 

18 June 2021

g)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZVZZFGMZM
Date   Source Headline
30th Oct 20254:58 pmRNSHolding(s) in Company
28th Oct 20254:04 pmRNSHolding(s) in Company
27th Oct 20257:00 amRNSConfirmation of receipt of £860k R&D tax credits
24th Oct 202510:12 amRNSHolding(s) in Company
23rd Oct 20259:09 amRNSHolding(s) in Company
21st Oct 202510:08 amRNSHolding(s) in Company
17th Oct 202510:26 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSHolding(s) in Company
16th Oct 20252:31 pmRNSHolding(s) in Company
16th Oct 202512:15 pmRNSHolding(s) in Company
15th Oct 20259:48 amRNSHolding(s) in Company
10th Oct 20252:34 pmRNSHolding(s) in Company
10th Oct 20259:56 amRNSHolding(s) in Company
10th Oct 20257:01 amRNSHolding(s) in Company
10th Oct 20257:00 amRNS$4m balance sheet improvement with bond conversion
9th Oct 20254:43 pmRNSHolding(s) in Company
7th Oct 20253:03 pmRNSHolding(s) in Company
3rd Oct 20252:32 pmRNSHolding(s) in Company
2nd Oct 20252:57 pmRNSHolding(s) in Company
1st Oct 20252:43 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
1st Oct 20257:00 amRNSCE Mark application submission
30th Sep 20254:02 pmRNSHolding(s) in Company
29th Sep 20255:18 pmRNSHolding(s) in Company
29th Sep 20252:28 pmRNSHolding(s) in Company
29th Sep 20259:32 amRNSHolding(s) in Company
29th Sep 20257:00 amRNSHolding(s) in Company
26th Sep 202512:17 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNS£7.05m total gross proceeds from Fundraise
24th Sep 20252:00 pmRNSUpdate Regarding Forward Guidance
24th Sep 202510:00 amRNSAdditional Subscription for 11m Shares
23rd Sep 20257:00 amRNSInvestor Presentation and Revised Revenue Guidance
22nd Sep 20255:30 pmRNSResult of Fundraise
22nd Sep 20257:01 amRNSWRAP Retail Offer for up to £500,000
22nd Sep 20257:00 amRNSProposed Fundraise
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20256:26 pmRNSHolding(s) in Company
16th Sep 20257:00 amRNSHolding(s) in Company
15th Sep 20257:00 amRNSTempus AI Inc, collaboration agreement
11th Sep 20255:14 pmRNSHolding(s) in Company
10th Sep 20254:32 pmRNSHolding(s) in Company
2nd Sep 202512:46 pmRNSHolding(s) in Company
1st Sep 202511:18 amRNSHolding(s) in Company
29th Aug 20259:25 amRNSHolding(s) in Company
26th Aug 202511:45 amRNSHolding(s) in Company
22nd Aug 20255:11 pmRNSHolding(s) in Company
22nd Aug 20251:30 pmRNSHolding(s) in Company
29th Jul 20257:00 amRNSServices contract with Joslin and Pharma Partner
17th Jul 20257:01 amRNSPartnership with MVP Health Care
17th Jul 20257:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.